Article
Generics Behaving Badly: Carve Outs, Off-Label Uses
Authors
-
- Name
- Person title
- Senior Principal
Law360, New York (May 04, 2009)
Patents have long been the crown jewels of the pharma industry. They protect pioneer therapies from generic competition and underwrite the enormous investment required for new drug research and development.
However, with an estimated $65 billion of drugs coming off patent protection in the next five years, generics stand ready to cash in on this bonanza. As the competitive landscape undergoes enormous changes, pioneers need to coordinate their IP and regulatory strategies to protect new investments in old drugs.
To read more, please click here.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.